Ep. 104 - Biotech Shows Support for Ukraine, Plus Latest Intellia Data
BioCentury This Week
00:00
Is This the Proof of Principlefal Genating in Vivo?
This is an up date from the clinical trial results that were reported last june that doubled the company's share price. They found that at the higher dose, they're able to knock down the gen that's ultimately responsible for trans thyraten amelidosis even more than in the lower dose. So i asked the co john leonard, that this morning, and he said that they think they had their proof of principle in june. That's when they started ramping up their pipe line to take advantage of this first move or advantage that they have.
Transcript
Play full episode
